Aster DM Healthcare Ltd
Aster DM Healthcare Limited is one of the largest integrated private healthcare service providers operating in GCC (Gulf Cooperation Council) countries and an emerging player in India. With an inherent emphasis on clinical excellence, it is one of the few entities in the world with a strong presence across primary, secondary, tertiary and quaternary healthcare. [1]
- Market Cap ₹ 16,579 Cr.
- Current Price ₹ 332
- High / Low ₹ 558 / 294
- Stock P/E 133
- Book Value ₹ 91.3
- Dividend Yield 0.60 %
- ROCE 4.38 %
- ROE 2.90 %
- Face Value ₹ 10.0
Pros
- Company has reduced debt.
- Debtor days have improved from 55.5 to 23.0 days.
Cons
- Stock is trading at 3.64 times its book value
- The company has delivered a poor sales growth of -14.2% over past five years.
- Company has a low return on equity of 9.21% over last 3 years.
- Company might be capitalizing the interest cost
- Promoters have pledged 98.9% of their holding.
- Working capital days have increased from 123 days to 297 days
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Sector: Healthcare Industry: Healthcare
Quarterly Results
Consolidated Figures in Rs. Crores / View Standalone
Profit & Loss
Consolidated Figures in Rs. Crores / View Standalone
Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
1,922 | 2,871 | 3,876 | 5,250 | 5,931 | 6,721 | 7,963 | 8,652 | 8,608 | 10,253 | 11,933 | 3,699 | |
1,660 | 2,421 | 3,370 | 4,805 | 5,582 | 6,089 | 6,886 | 7,187 | 7,506 | 8,720 | 10,307 | 3,132 | |
Operating Profit | 261 | 451 | 506 | 445 | 349 | 632 | 1,077 | 1,465 | 1,103 | 1,533 | 1,626 | 567 |
OPM % | 14% | 16% | 13% | 8% | 6% | 9% | 14% | 17% | 13% | 15% | 14% | 15% |
11 | 19 | 23 | 25 | 453 | 177 | -155 | -158 | 53 | 51 | 79 | 32 | |
Interest | 45 | 48 | 79 | 189 | 371 | 204 | 205 | 391 | 334 | 307 | 390 | 110 |
Depreciation | 76 | 111 | 144 | 243 | 322 | 298 | 306 | 586 | 618 | 641 | 780 | 220 |
Profit before tax | 151 | 310 | 306 | 38 | 108 | 308 | 410 | 330 | 205 | 637 | 535 | 268 |
Tax % | 4% | 9% | 11% | 78% | 10% | 8% | 10% | 5% | 13% | 6% | 11% | 21% |
149 | 284 | 272 | 8 | 98 | 282 | 367 | 315 | 178 | 601 | 475 | 212 | |
EPS in Rs | 7.26 | 4.69 | 7.00 | 0.20 | 2.52 | 5.32 | 6.59 | 5.54 | 2.96 | 10.53 | 8.51 | 2.59 |
Dividend Payout % | -0% | 35% | -0% | -0% | -0% | -0% | -0% | -0% | -0% | -0% | -0% | -0% |
Compounded Sales Growth | |
---|---|
10 Years: | 3% |
5 Years: | -14% |
3 Years: | -25% |
TTM: | -69% |
Compounded Profit Growth | |
---|---|
10 Years: | -3% |
5 Years: | -24% |
3 Years: | -5% |
TTM: | -70% |
Stock Price CAGR | |
---|---|
10 Years: | % |
5 Years: | 22% |
3 Years: | 28% |
1 Year: | 11% |
Return on Equity | |
---|---|
10 Years: | 8% |
5 Years: | 9% |
3 Years: | 9% |
Last Year: | 3% |
Balance Sheet
Consolidated Figures in Rs. Crores / View Standalone
Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Equity Capital | 125 | 375 | 389 | 403 | 403 | 505 | 505 | 497 | 497 | 500 | 500 | 500 |
Reserves | 654 | 536 | 1,096 | 17 | 1,472 | 2,327 | 2,709 | 2,775 | 2,875 | 3,080 | 3,574 | 4,060 |
505 | 886 | 1,091 | 3,321 | 2,758 | 2,352 | 2,788 | 5,605 | 4,804 | 5,282 | 6,075 | 1,384 | |
856 | 1,097 | 1,834 | 2,003 | 2,171 | 2,296 | 2,926 | 3,528 | 3,444 | 3,661 | 4,687 | 12,048 | |
Total Liabilities | 2,140 | 2,894 | 4,409 | 5,743 | 6,804 | 7,479 | 8,928 | 12,405 | 11,620 | 12,521 | 14,836 | 17,991 |
872 | 1,087 | 2,237 | 2,507 | 3,520 | 3,738 | 4,289 | 7,124 | 6,749 | 7,009 | 9,052 | 3,175 | |
CWIP | 185 | 357 | 197 | 358 | 290 | 402 | 550 | 736 | 934 | 998 | 279 | 170 |
Investments | 6 | 7 | 3 | 39 | 32 | 38 | 22 | 34 | 63 | 45 | 80 | 17 |
1,077 | 1,442 | 1,972 | 2,839 | 2,962 | 3,302 | 4,067 | 4,511 | 3,874 | 4,470 | 5,425 | 14,629 | |
Total Assets | 2,140 | 2,894 | 4,409 | 5,743 | 6,804 | 7,479 | 8,928 | 12,405 | 11,620 | 12,521 | 14,836 | 17,991 |
Cash Flows
Consolidated Figures in Rs. Crores / View Standalone
Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
236 | 203 | 361 | 537 | 601 | 1,223 | 1,569 | 1,314 | 1,834 | 158 | |||
-439 | -775 | -1,136 | -522 | -702 | -658 | -333 | -563 | -951 | -885 | |||
203 | 578 | 654 | 46 | 134 | -675 | -1,116 | -686 | -817 | 1,053 | |||
Net Cash Flow | -1 | 5 | -122 | 61 | 33 | -110 | 120 | 65 | 66 | 326 |
Ratios
Consolidated Figures in Rs. Crores / View Standalone
Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Debtor Days | 95 | 86 | 83 | 93 | 79 | 84 | 93 | 100 | 86 | 72 | 71 | 23 |
Inventory Days | 84 | 71 | 93 | 92 | 102 | 111 | 110 | 138 | 122 | 129 | 135 | 44 |
Days Payable | 213 | 176 | 178 | 187 | 151 | 150 | 153 | 303 | 290 | 267 | 309 | 183 |
Cash Conversion Cycle | -34 | -18 | -2 | -1 | 30 | 45 | 50 | -65 | -83 | -66 | -102 | -116 |
Working Capital Days | 82 | 61 | 69 | 68 | 57 | 59 | 57 | 40 | 38 | 40 | 32 | 297 |
ROCE % | 18% | 14% | 6% | 1% | 7% | 13% | 12% | 6% | 10% | 9% | 4% |
Documents
Announcements
- Board Meeting Intimation for Meeting Of The Board Of The Company To Be Held On 31St July, 2024 1d
-
Announcement under Regulation 30 (LODR)-Acquisition
19 Jul - Malabar Institute of Medical Sciences Limited ("MIMS"), a material subsidiary of Aster DM Healthcare Limited ("Company"), has entered into definitive agreements on 19th July, 2024 …
- Intimation Under Regulation 30 Of SEBI (LODR) Regulations, 2015 15 Jul
-
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
15 Jul - Depositories and Participants) Regulations, 2018, please find enclosed confirmation certificate for the quarter ended June 30, 2024.
- Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011 5 Jul
Annual reports
Concalls
-
Jun 2024Transcript PPT
-
May 2024TranscriptNotesPPT
-
Feb 2024Transcript PPT
-
Feb 2024TranscriptNotesPPT
-
Dec 2023Transcript PPT
-
Nov 2023TranscriptNotesPPT
-
Nov 2023TranscriptNotesPPT
-
Aug 2023Transcript PPT
-
Jun 2023Transcript PPT REC
-
Feb 2023Transcript PPT
-
Nov 2022Transcript PPT
-
Aug 2022TranscriptPPT
-
Aug 2022Transcript PPT
-
May 2022Transcript PPT
-
Feb 2022Transcript PPT
-
Nov 2021Transcript PPT
-
Sep 2021TranscriptPPT
-
Aug 2021Transcript PPT
-
Jun 2021Transcript PPT
-
Mar 2021TranscriptPPT
-
Feb 2021Transcript PPT
-
Dec 2020TranscriptPPT
-
Nov 2020Transcript PPT
-
Aug 2020Transcript PPT
-
Jun 2020Transcript PPT
-
Jun 2020TranscriptNotesPPT
-
Feb 2020Transcript PPT
-
Feb 2020TranscriptNotesPPT
-
Nov 2019Transcript PPT
-
Sep 2019Transcript PPT
-
Aug 2019Transcript PPT
-
Jun 2019Transcript PPT
-
May 2019TranscriptPPT
-
Mar 2019TranscriptPPT
-
Feb 2019Transcript PPT
-
Nov 2018TranscriptNotesPPT
-
Sep 2018TranscriptPPT
-
Aug 2018Transcript PPT
-
Jun 2018Transcript PPT
Demerger[1]
The company is demerging its GCC and India operations into separate entities for operational efficiencies. Post-segregation, Aster DM Healthcare Limited will be focused on India business. The GCC Business will be separated from Aster DM Healthcare Limited to create Aster GCC. GCC Business will be acquired by Alpha GCC Holdings Limited for Enterprise Value of US$1,651.2m (~Rs. 13,540 crs). At the closing of the Transaction, Fajr Capital & its consortium members will own ~65% and a Promoter entity will own the remaining ~35% stake in the GCC Business through Aster GCC. The transaction is expected to complete by Q4 FY24.